Literature DB >> 35324388

Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Volodymyr P Tryndyak1, Rose A Willett1, Mark I Avigan2, Arun J Sanyal3, Frederick A Beland1, Ivan Rusyn4, Igor P Pogribny1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease, and patient susceptibility to its onset and progression is influenced by several factors. In this study, we investigated whether altered hepatic DNA methylation in liver tissue correlates with the degree of severity of NAFLD-like liver injury induced by a high-fat and high-sucrose (HF/HS) diet in Collaborative Cross (CC) mice. Using genome-wide targeted bisulphite DNA methylation next-generation sequencing, we found that mice with different non-alcoholic fatty liver (NAFL) phenotypes could be distinguished by changes in hepatic DNA methylation profiles. Specifically, NAFL-prone male CC042 mice exhibited more prominent DNA methylation changes compared with male CC011 mice and female CC011 and CC042 mice that developed only a mild NAFL phenotype. Moreover, these mouse strains demonstrated different patterns of DNA methylation. While the HF/HS diet induced both DNA hypomethylation and DNA hypermethylation changes in all the mouse strains, the NAFL-prone male CC042 mice demonstrated a global predominance of DNA hypermethylation, whereas a more pronounced DNA hypomethylation pattern developed in the mild-NAFL phenotypic mice. In a targeted analysis of selected genes that contain differentially methylated regions (DMRs), we identified NAFL phenotype-associated differences in DNA methylation and gene expression of the Apoa4, Gls2, and Apom genes in severe NAFL-prone mice but not in mice with mild NAFL phenotypes. These changes in the expression of Apoa4 and Gls2 coincided with similar findings in a human in vitro cell model of diet-induced steatosis and in patients with NAFL. These results suggest that changes in the expression and DNA methylation status of these three genes may serve as a set of predictive markers for the development of NAFLD.

Entities:  

Keywords:  Collaborative Cross mice; DNA methylation; GLS2; gene expression; non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2022        PMID: 35324388      PMCID: PMC9586642          DOI: 10.1080/15592294.2022.2043590

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.861


  49 in total

1.  Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.

Authors:  Carlos Jose Pirola; Tomas Fernández Gianotti; Adriana Laura Burgueño; Manuel Rey-Funes; Cesar Fabian Loidl; Pablo Mallardi; Julio San Martino; Gustavo Osvaldo Castaño; S Sookoian
Journal:  Gut       Date:  2012-08-09       Impact factor: 23.059

Review 2.  Past, present and future perspectives in nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06       Impact factor: 46.802

Review 3.  Genetics and epigenetics of NAFLD and NASH: Clinical impact.

Authors:  Mohammed Eslam; Luca Valenti; Stefano Romeo
Journal:  J Hepatol       Date:  2017-11-06       Impact factor: 25.083

4.  Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.

Authors:  Malte P Suppli; Kristoffer T G Rigbolt; Sanne S Veidal; Sara Heebøll; Peter Lykke Eriksen; Mia Demant; Jonatan I Bagger; Jens Christian Nielsen; Denise Oró; Sebastian W Thrane; Asger Lund; Charlotte Strandberg; Merete J Kønig; Tina Vilsbøll; Niels Vrang; Karen L Thomsen; Henning Grønbæk; Jacob Jelsing; Henrik H Hansen; Filip K Knop
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-01-17       Impact factor: 4.052

5.  Hepatic DPP4 DNA Methylation Associates With Fatty Liver.

Authors:  Christian Baumeier; Sophie Saussenthaler; Anne Kammel; Markus Jähnert; Luisa Schlüter; Deike Hesse; Mickaël Canouil; Stephane Lobbens; Robert Caiazzo; Violeta Raverdy; François Pattou; Emma Nilsson; Jussi Pihlajamäki; Charlotte Ling; Philippe Froguel; Annette Schürmann; Robert W Schwenk
Journal:  Diabetes       Date:  2016-10-10       Impact factor: 9.461

Review 6.  Apolipoprotein A-IV: a protein intimately involved in metabolism.

Authors:  Fei Wang; Alison B Kohan; Chun-Min Lo; Min Liu; Philip Howles; Patrick Tso
Journal:  J Lipid Res       Date:  2015-02-01       Impact factor: 5.922

7.  Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.

Authors:  Melissa A VerHague; Dongmei Cheng; Richard B Weinberg; Gregory S Shelness
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-09-12       Impact factor: 8.311

8.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications.

Authors:  Felix Krueger; Simon R Andrews
Journal:  Bioinformatics       Date:  2011-04-14       Impact factor: 6.937

9.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation.

Authors:  Cole Trapnell; Brian A Williams; Geo Pertea; Ali Mortazavi; Gordon Kwan; Marijke J van Baren; Steven L Salzberg; Barbara J Wold; Lior Pachter
Journal:  Nat Biotechnol       Date:  2010-05-02       Impact factor: 54.908

10.  Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis.

Authors:  Pei-Wen Wang; Yu-Ching Hung; Tung-Ho Wu; Mu-Hong Chen; Chau-Ting Yeh; Tai-Long Pan
Journal:  Oncotarget       Date:  2017-10-06
View more
  1 in total

1.  Brain gene expression differences related to ethanol preference in the collaborative cross founder strains.

Authors:  Justin Q Anderson; Priscila Darakjian; Robert Hitzemann; Denesa R Lockwood; Tamara J Phillips; Angela R Ozburn
Journal:  Front Behav Neurosci       Date:  2022-09-23       Impact factor: 3.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.